• Mutation; HGNC; HGNC:795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
  

PubMed=2598402; DOI=10.1007/BF00692343
Alaoui-Jamali M.A., Yin M.-B., Mazzoni A., Bankusli I., Rustum Y.M.
Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.
Cancer Chemother. Pharmacol. 25:77-83(1989)

PubMed=2751261
Mazzoni A., Trave F., Canti G., Franco P.
Effect of the tiapamil analog RO11-2933 on cellular sensitivity to antitumor drugs in sensitive and multidrug resistant human ovarian cancer cells.
Anticancer Res. 9:367-371(1989)

PubMed=8012063
Cimoli G., Valenti M., Parodi S., Mazzoni A., De Sessa F., Conte P., Russo P.
Reversal of 'atypical'-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Oncol. Res. 5:311-323(1993)

PubMed=7713987; DOI=10.1007/BF01198097
Cimoli G., Valenti M., Noviello E., Parodi S., Mazzoni A., Rovini E., De Sessa F., Russo P.
'Atypical' multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
J. Cancer Res. Clin. Oncol. 121:155-163(1995)